Frequent copy number variations of PI3K/AKT pathway and aberrant protein expressions of PI3K subunits are associated with inferior survival in diffuse large B cell lymphoma

被引:40
|
作者
Cui, Wenli [1 ,2 ,3 ,4 ]
Cai, Ying [1 ,2 ,3 ]
Wang, Weige [1 ,2 ,3 ]
Liu, Zebing [1 ,2 ,3 ]
Wei, Ping [1 ,2 ,3 ]
Bi, Rui [1 ,2 ,3 ]
Chen, Weixiang [1 ,2 ,3 ]
Sun, Menghong [1 ,2 ,3 ]
Zhou, Xiaoyan [1 ,2 ,3 ]
机构
[1] Fudan Univ, Shanghai Canc Ctr, Dept Pathol, Shanghai 200032, Peoples R China
[2] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China
[3] Fudan Univ, Inst Pathol, Shanghai 200032, Peoples R China
[4] Xinjiang Med Univ, Affiliated Hosp 1, Dept Pathol, Urumqi 830054, Xinjiang Uygur, Peoples R China
关键词
DLBCL; CNV; PI3K/AKT; Subunits; Survival; INTEGRATIVE GENOMIC ANALYSIS; GENE-EXPRESSION; AKT; PIK3CA; GROWTH; ISOFORMS; ROLES;
D O I
10.1186/1479-5876-12-10
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: It has been reported that the PI3K/AKT signaling pathway is activated in diffuse large B-cell lymphoma (DLBCL), PI3K constitutive activation plays a crucial role in PI3K/AKT pathway. However, the copy number variations (CNVs) of PI3K subunits on gene level remain unknown in DLBCL. Therefore, the aim of the study is to investigate the CNV of PI3K subunits and their relationship with clinicopathological features exploring the possible mechanism underlying of PI3K activation in DLBCL. Methods: CNV of 12 genes in the PI3K/AKT pathway was detected by NanoString nCounter in 60 de novo DLBCLs and 10 reactive hyperplasia specimens as controls. Meanwhile, immunohistochemistry (IHC) was performed to examine the expression of p110 alpha, p110 beta, p110 gamma, p110 delta, and pAKT on DLBCL tissue microarrays. Results: All PI3K and AKT subunits, except for PIK3R1, had various CNVs in the form of copy number amplifications and copy number losses. Their rates were in the range of 8.3-20.0%. Of them PIK3CA and PIK3CB gene CNVs were significantly associated with decreased overall survival (P = 0.029 and P = 0.019, respectively). IHC showed that the frequency of strong positive expression of p110 alpha, p110 beta, p110 gamma, and p110 delta were 26.7%, 25.0%, 18.3%, and 25.0% respectively, and they were found to be associated with decreased survival (P = 0.022, P = 0.015, P = 0.015, and P = 0.008, respectively). Expression of p110 alpha was not only significantly associated with CNVs of PIK3CA (P = 0.002) but also positively correlated with strong positive expression of pAKT (P = 0.026). Conclusions: CNV of PIK3CA is highly associated with aberrant p110a protein expression and subsequent activation of PI3K/AKT pathway. CNVs of PIK3CA and PIK3CB, and aberrant protein expression of p110 isoforms are of great important value for predicting inferior prognosis in DLBCL. Frequent CNVs of PI3K/AKT subunits may play an important role in the tumorigenesis of DLBCL.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Frequent copy number variations of PI3K/AKT pathway and aberrant protein expressions of PI3K subunits are associated with inferior survival in diffuse large B cell lymphoma
    Wenli Cui
    Ying Cai
    Weige Wang
    Zebing Liu
    Ping Wei
    Rui Bi
    Weixiang Chen
    Menghong Sun
    Xiaoyan Zhou
    Journal of Translational Medicine, 12
  • [2] PI3Kδ inhibition causes feedback activation of PI3Kα in the ABC subtype of diffuse large B-cell lymphoma
    Pongas, Georgios N.
    Annunziata, Christina M.
    Staudt, Louis M.
    ONCOTARGET, 2017, 8 (47) : 81794 - 81802
  • [3] TCL1 as a hub protein associated with the PI3K/AKT signaling pathway in diffuse large B-cell lymphoma based on proteomics methods
    Gao, Hai-Xia
    Li, Si-Jing
    Niu, Jing
    Ma, Zhi-Ping
    Nuerlan, Aijiang
    Xue, Jing
    Wang, Meng-Bo
    Wen-Li Cui
    Abulajiang, Gulinaer
    Sang, Wei
    Zhang, Wei
    Li, Xin-Xia
    PATHOLOGY RESEARCH AND PRACTICE, 2020, 216 (02)
  • [4] CAPG facilitates diffuse large B-cell lymphoma cell progression through PI3K/AKT signaling pathway
    Wang, Ganggang
    Liu, Hu
    An, Lin
    Hou, Shuling
    Zhang, Qiaohua
    HUMAN IMMUNOLOGY, 2022, 83 (12) : 832 - 842
  • [5] The PI3K/AKT/MTOR signaling pathway: The role of PI3K and AKT inhibitors in breast cancer
    Huemer F.
    Bartsch R.
    Gnant M.
    Current Breast Cancer Reports, 2014, 6 (2) : 59 - 70
  • [6] The PI3K/AKT Pathway and Renal Cell Carcinoma
    Huifang Guo
    Peter German
    Shanshan Bai
    Sean Barnes
    Wei Guo
    Xiangjie Qi
    Hongxiang Lou
    Jiyong Liang
    Eric Jonasch
    Gordon B.Mills
    Zhiyong Ding
    Journal of Genetics and Genomics, 2015, 42 (07) : 343 - 353
  • [7] Leptin receptor expression and its association with PI3K/AKT signaling pathway in diffuse large B-cell lymphoma
    Uddin, Shahab
    Bu, Rong
    Ahmed, Maqbool
    Hussain, Azhar R.
    Ajarim, Dahish
    Al-Dayel, Fouad
    Bavi, Prashant
    Al-Kuraya, Khawla S.
    LEUKEMIA & LYMPHOMA, 2010, 51 (07) : 1305 - 1314
  • [8] Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab
    Xu, Zi-Zhen
    Xia, Zu-Guang
    Wang, Ai-Hua
    Wang, Wen-Fang
    Liu, Zhi-Yin
    Chen, Li-Yun
    Li, Jun-Min
    ANNALS OF HEMATOLOGY, 2013, 92 (10) : 1351 - 1358
  • [9] The PI3K pathway in B cell metabolism
    Jellusova, Julia
    Rickert, Robert C.
    CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2016, 51 (05) : 359 - 378
  • [10] Status of PI3K/Akt/mTOR Pathway Inhibitors in Lymphoma
    Westin, Jason R.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (05) : 335 - 342